Cuiqing Ma

Prof. Cuiqing Ma

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Pharmacological Research
Verified
Journal Article
Open access
ZZZheng-Zheng Zhang
Zheng-Zheng Zhang
TWTian Wang
Tian Wang
XWXiao-Feng Wang
Xiao-Feng Wang
YZYu-Qing Zhang
Yu-Qing Zhang
SSShu-Xia Song
Shu-Xia Song
CMCuiqing Ma
Cuiqing Ma
Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of TCM memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

15 March 2023 in Inflammation
Verified
Journal Article
Closed access
PDF file
JNJingyuan Ning
Jingyuan Ning
XFXiaoqing Fan
Xiaoqing Fan
KSKeran Sun
Keran Sun
XWXuan Wang
Xuan Wang
HLHongru Li
Hongru Li
CMCuiqing Ma
Cuiqing Ma

21 September 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
JWJiachao Wang
Jiachao Wang
CMCuiqing Ma
Cuiqing Ma
MLmiao li
miao li
XGXue Gao
Xue Gao
HWHao Wu
Hao Wu
LWLin Wei
Lin Wei
Streptococcus pyogenes (group A Streptococcus; GAS), a Gram-positive coccal bacterium, poses a significant global disease burden, especially in low- and middle-income countries. Its manifestations can range from pharyngitis and skin infection to severe and aggressive diseases, such as necrotizing fasciitis and streptococcal toxic shock syndrome. At present, although GAS is still sensitive to penicillin, there are cases of treatment failure for GAS pharyngitis, and antibiotic therapy does not universally prevent subsequent disease. In addition to strengthening global molecular epidemiological surveillance and monitoring of antibiotic resistance, developing a safe and effective licensed vaccine against GAS would be the most effective way to broadly address GAS-related diseases. Over the past decades, the development of GAS vaccines has been stalled, mainly because of the wide genetic heterogeneity of GAS and the diverse autoimmune responses to GAS. With outbreaks of scarlet fever in various countries in recent years, accelerating the development of a safe and effective vaccine remains a high priority. When developing a GAS vaccine, many factors need to be considered, including the selection of antigen epitopes, avoidance of self-response, and vaccine coverage. Given the challenges in GAS vaccine development, this review describes the important virulence factors that induce disease by GAS infection and how this has influenced the progression of vaccine development efforts, focusing on several candidate vaccines that are further along in development.

20 March 2023 in Molecular Medicine
Verified
Journal Article
Open access
PDF file
JNJingyuan Ning
Jingyuan Ning
KSKeran Sun
Keran Sun
XWXuan Wang
Xuan Wang
XFXiaoqing Fan
Xiaoqing Fan
KJKeqi Jia
Keqi Jia
CMCuiqing Ma
Cuiqing Ma
Background: Although significant advances have been made in intensive care medicine and antibacterial treatment, sepsis is still a common disease with high mortality. The condition of sepsis patients changes rapidly, and each hour of delay in the administration of appropriate antibiotic treatment can lead to a 4–7% increase in fatality. Therefore, early diagnosis and intervention may help improve the prognosis of patients with sepsis. Methods: We obtained single-cell sequencing data from 12 patients. This included 14,622 cells from four patients with bacterial infectious sepsis and eight patients with sepsis admitted to the ICU for other various reasons. Monocyte differentiation trajectories were analyzed using the “monocle” software, and differentiation-related genes were identified. Based on the expression of differentiation-related genes, 99 machine-learning combinations of prognostic signatures were obtained, and risk scores were calculated for all patients. The “scissor” software was used to associate high-risk and low-risk patients with individual cells. The “cellchat” software was used to demonstrate the regulatory relationships between high-risk and low-risk cells in a cellular communication network. The diagnostic value and prognostic predictive value of Enah/Vasp-like (EVL) were determined. Clinical validation of the results was performed with 40 samples. The “CBNplot” software based on Bayesian network inference was used to construct EVL regulatory networks. Results: We systematically analyzed three cell states during monocyte differentiation. The differential analysis identified 166 monocyte differentiation-related genes. Among the 99 machine-learning combinations of prognostic signatures constructed, the Lasso + CoxBoost signature with 17 genes showed the best prognostic prediction performance. The highest percentage of high-risk cells was found in state one. Cell communication analysis demonstrated regulatory networks between high-risk and low-risk cell subpopulations and other immune cells. We then determined the diagnostic and prognostic value of EVL stabilization in multiple external datasets. Experiments with clinical samples demonstrated the accuracy of this analysis. Finally, Bayesian network inference revealed potential network mechanisms of EVL regulation. Conclusions: Monocyte differentiation-related prognostic signatures based on the Lasso + CoxBoost combination were able to accurately predict the prognostic status of patients with sepsis. In addition, low EVL expression was associated with poor prognosis in sepsis.

29 July 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YYYujia Yang
Yujia Yang
JCJinlei Cui
Jinlei Cui
YKYajie Kong
Yajie Kong
YHYu Hou
Yu Hou
CMCuiqing Ma
Cuiqing Ma
The tumor microenvironment (TME) contains cells that regulate medication response and cancer growth in a major way. Tumor immunology research has been rejuvenated and cancer treatment has been changed by immunotherapy, a rapidly developing therapeutic approach. The growth patterns of tumor cells in vivo and the heterogeneity, complexity, and individuality of tumors produced from patients are not reflected in traditional two-dimensional tumor cell profiles. On the other hand, an in vitro three-dimensional (3D) model called the organoid model is gaining popularity. It can replicate the physiological and pathological properties of the original tissues in vivo. Tumor cells are the source of immune organoids. The TME characteristics can be preserved while preserving the variety of tumors by cultivating epithelial tumor cells with various stromal and immunological components. In addition to having genetic and physical similarities to human diseases and the ability to partially reconstruct the complex structure of tumors, these models are now widely used in research fields including cancer, developmental biology, regenerative mechanisms, drug development, disease modeling, and organ transplantation. This study reviews the function of organoids in immunotherapy and the tumor immune milieu. We also discuss current developments and suggest translational uses of tumor organoids in immuno-oncology research, immunotherapy modeling, and precision medicine.

1 January 2025 in Research
Verified
Journal Article
Open access
XWXuan Wang
Xuan Wang
JNJingyuan Ning
Jingyuan Ning
LZLiang Zhou
Liang Zhou
HLHongru Li
Hongru Li
JCJinlei Cui
Jinlei Cui
CMCuiqing Ma
Cuiqing Ma
Sepsis remains a leading global cause of death, with immune heterogeneity’s molecular mechanisms poorly understood. This study analyzed 1,862 human peripheral blood samples, constructing a molecular interaction disturbance network that first revealed the network biology underlying sepsis immune heterogeneity. We identified 3 sepsis subtypes with marked different prognostic characteristics, with the C1 subtype showing the worst prognosis characterized by severe CD4 + T cell exhaustion—validated across 10 independent cohorts. Integrating single-cell transcriptomics from over 450,000 cells, proteomics, and functional validation, we identified monocyte-derived matrix metalloproteinase-9 (MMP9) as a key regulator driving CD4 + T cell dysfunction. Mechanistically, MMP9 modulates T cell exhaustion through dual mechanisms: promoting leukocyte-associated immunoglobulin-like receptor-1 (Lair-1) aggregation on T cell membranes, directly inhibiting zeta chain of T cell receptor associated protein kinase 70 (ZAP70) phosphorylation in T cell receptor signaling, while impairing Ca 2+ -release-activated Ca 2+ channel function and intracellular calcium clearance, causing calcium dysregulation that blocks nuclear factor of activated T cells (NFAT) activation and nuclear translocation. The selective MMP9 inhibitor MMP9-in-1 effectively reversed T cell dysfunction, restored calcium homeostasis and NFAT nuclear translocation, markedly enhanced CD4 + T cell interleukin-2 and interferon-γ production, and reduced programmed cell death protein 1 expression. This work establishes a comprehensive translational framework from molecular network disturbances to clinical phenotypes, advancing sepsis immunopathophysiology understanding and providing effective targets for the treatment of sepsis patients.